Pharmaceuticals, Biotechnology and Life Sciences
Bayer said on Friday it would cut its full-year earnings forecast due to high inventories at crop protection distributors in Brazil and a weaker-than-expected consumer health business.
The U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the New Drug Application (NDA) for Bayer’s copanlisib for the treatment of relapsed or refractory follicular lymphoma (FL) patients who have received at least two prior therapies.
Bayer has reported net income of €2.083 million for Q1 2017 which is 37.9 percent higher comparing the same period last year.
Bayer has partnered up with Goodbye Malaria to support the objectives of Ending Malaria for Good in Southern Africa.
Bayer AG and Janssen Pharmaceuticals reported results from a study called Einstein Choice on Saturday.
Bayer has reported net income of €4,531 million which is 10.2% increase comparing to 2015 (€4,110 million). The company reported earnings growth in pharmaceutical activities, while other activities remain steady.
Bayer’s and Janssen R&D’s drug for cardiac situations has already met its primary goals in the early third phase of testing, the companies said today, which concludes the testing.
Japanese Ministry of Health, Labour and Welfare (MHLW) has granted priority review to Bayer Yakuhin for regorafenib in the second-line…
Bayer has started off the new year with another approval from theU.S. Food and Drug Administration (FDA).
In 2016, mega deals became ever more transformative.
German drug and crop chemical maker Bayer AG announced its $66 billion takeover of U.S. agrochemicals company Monsanto Co, while ChemChina signed a $43 billion acquisition of Swiss seeds group Syngenta AG, as consolidation in the sector intensified.